A citation-based method for searching scientific literature

Hiroshi Miura, Kazuhiko Sakaguchi, Yuko Okada, Tomoko Yamada, Natsu Otowa-Suematsu, Anna So, Hisako Komada, Yushi Hirota, Takeshi Ohara, Yasuo Kuroki, Kenta Hara, Tomokazu Matsuda, Minoru Kishi, Akihiko Takeda, Kazuki Yokota, Yoshikazu Tamori, Wataru Ogawa. J Diabetes Investig 2019
Times Cited: 10







List of co-cited articles
13 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
30

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats.
James J Devenny, Helen E Godonis, Susan J Harvey, Suzanne Rooney, Mary J Cullen, Mary Ann Pelleymounter. Obesity (Silver Spring) 2012
127
20

Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment.
Ichiro Horie, Norio Abiru, Ryoko Hongo, Takeshi Nakamura, Ayako Ito, Ai Haraguchi, Shoko Natsuda, Ikuko Sagara, Takao Ando, Atsushi Kawakami. Diabetes Res Clin Pract 2018
20
20

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Giulia Ferrannini, Thomas Hach, Susanne Crowe, Arjun Sanghvi, Kevin D Hall, Ele Ferrannini. Diabetes Care 2015
181
20

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
Kumiko Shiba, Kyoichiro Tsuchiya, Chikara Komiya, Yasutaka Miyachi, Kentaro Mori, Noriko Shimazu, Shinobu Yamaguchi, Naomi Ogasawara, Makoto Katoh, Michiko Itoh,[...]. Sci Rep 2018
56
20

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Aino Latva-Rasku, Miikka-Juhani Honka, Joel Kullberg, Nina Mononen, Terho Lehtimäki, Juha Saltevo, Anna K Kirjavainen, Virva Saunavaara, Patricia Iozzo, Lars Johansson,[...]. Diabetes Care 2019
62
20


Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani,[...]. J Clin Invest 2014
477
20

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
634
20


Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
C David Mazer, Gregory M T Hare, Philip W Connelly, Richard E Gilbert, Nadine Shehata, Adrian Quan, Hwee Teoh, Lawrence A Leiter, Bernard Zinman, Peter Jüni,[...]. Circulation 2020
86
20

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
20


Adipose tissue: the link between obesity and cardiovascular disease.
Vanessa DeClercq, Carla Taylor, Peter Zahradka. Cardiovasc Hematol Disord Drug Targets 2008
45
10

Optimal energy distribution of carbohydrate intake for Japanese elderly patients with type 2 diabetes: the Japanese Elderly Intervention Trial.
Chiemi Kamada, Hidenori Yoshimura, Ryota Okumura, Keiko Takahashi, Satoshi Iimuro, Yasuo Ohashi, Atsushi Araki, Hiroyuki Umegaki, Takashi Sakurai, Yukio Yoshimura,[...]. Geriatr Gerontol Int 2012
10
10

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).
Hiroki Nakajima, Sadanori Okada, Takako Mohri, Eiichiro Kanda, Naoyuki Inaba, Yoko Hirasawa, Hiroaki Seino, Hisamoto Kuroda, Toru Hiyoshi, Tetsuji Niiya,[...]. Diabetol Metab Syndr 2018
12
10

Skipping Breakfast is Correlated with Obesity.
Yoko Watanabe, Isao Saito, Ikuyo Henmi, Kana Yoshimura, Kotatsu Maruyama, Kanako Yamauchi, Tatsuhiro Matsuo, Tadahiro Kato, Takeshi Tanigawa, Taro Kishida,[...]. J Rural Med 2014
45
10

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
213
10

Patient perceptions of quality of life with diabetes-related complications and treatments.
Elbert S Huang, Sydney E S Brown, Bernard G Ewigman, Edward C Foley, David O Meltzer. Diabetes Care 2007
171
10

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Hiroaki Iijima, Takayuki Kifuji, Nobuko Maruyama, Nobuya Inagaki. Adv Ther 2015
27
10



Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
William T Cefalu, Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Leo Niskanen, John Xie, Dainius A Balis, William Canovatchel, Gary Meininger. Lancet 2013
504
10

Cohort profile: The Japan diabetes complications study: a long-term follow-up of a randomised lifestyle intervention study of type 2 diabetes.
Shiro Tanaka, Sachiko Tanaka, Satoshi Iimuro, Hidetoshi Yamashita, Shigehiro Katayama, Yasuo Ohashi, Yasuo Akanuma, Nobuhiro Yamada, Hirohito Sone. Int J Epidemiol 2014
34
10


Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
W Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J Davies. Metabolism 2018
90
10

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.
Atsushi Obata, Naoto Kubota, Tetsuya Kubota, Masahiko Iwamoto, Hiroyuki Sato, Yoshitaka Sakurai, Iseki Takamoto, Hisayuki Katsuyama, Yoshiyuki Suzuki, Masanori Fukazawa,[...]. Endocrinology 2016
83
10

Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.
Juan Pablo Domecq, Gabriela Prutsky, Aaron Leppin, M Bassam Sonbol, Osama Altayar, Chaitanya Undavalli, Zhen Wang, Tarig Elraiyah, Juan Pablo Brito, Karen F Mauck,[...]. J Clin Endocrinol Metab 2015
154
10


Dietary intake in Japanese patients with type 2 diabetes: Analysis from Japan Diabetes Complications Study.
Chika Horikawa, Yukio Yoshimura, Chiemi Kamada, Shiro Tanaka, Sachiko Tanaka, Akane Takahashi, Osamu Hanyu, Atsushi Araki, Hideki Ito, Akira Tanaka,[...]. J Diabetes Investig 2014
29
10

The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin.
Nicole M Gerlanc, Jennifer Cai, Joseph Tkacz, Susan C Bolge, Brenna L Brady. Diabetes Metab Syndr Obes 2017
5
20

Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients.
Nobuya Inagaki, Shin-Ichi Harashima, Hiroaki Iijima. Expert Opin Pharmacother 2018
11
10


Leptin and brain-adipose crosstalks.
Alexandre Caron, Syann Lee, Joel K Elmquist, Laurent Gautron. Nat Rev Neurosci 2018
85
10


Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Hideka Inoue, Katsutaro Morino, Satoshi Ugi, Sachiko Tanaka-Mizuno, Keiko Fuse, Itsuko Miyazawa, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida,[...]. J Diabetes Investig 2019
17
10

Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor.
Anna So, Kazuhiko Sakaguchi, Yuko Okada, Yasuko Morita, Tomoko Yamada, Hiroshi Miura, Natsu Otowa-Suematsu, Tomoaki Nakamura, Hisako Komada, Yushi Hirota,[...]. Endocr J 2020
5
20

Clinical characteristics of insulin resistance syndromes: A nationwide survey in Japan.
Takehito Takeuchi, Yasushi Ishigaki, Yushi Hirota, Yutaka Hasegawa, Tohru Yorifuji, Hiroko Kadowaki, Takashi Akamizu, Wataru Ogawa, Hideki Katagiri. J Diabetes Investig 2020
7
14

Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor.
Tetsushi Hamaguchi, Yushi Hirota, Takehito Takeuchi, Yasushi Nakagawa, Atsuko Matsuoka, Masaaki Matsumoto, Hiroyuki Awano, Kazumoto Iijima, Pei Chieng Cha, Wataru Satake,[...]. J Diabetes Investig 2018
11
10

Sodium-Glucose Cotransporter 2 Inhibitor Improves Complications of Lipodystrophy: A Case Report.
Yohei Kawana, Junta Imai, Shojiro Sawada, Tetsuya Yamada, Hideki Katagiri. Ann Intern Med 2017
10
10

Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: toward recommendation for molecular testing and management.
M Avila, D A Dyment, J V Sagen, J St-Onge, U Moog, B H Y Chung, S Mo, S Mansour, A Albanese, S Garcia,[...]. Clin Genet 2016
39
10


Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome.
Shuichi Nagashima, Tetsuji Wakabayashi, Naoko Saito, Manabu Takahashi, Kenta Okada, Ken Ebihara, Shun Ishibashi. J Diabetes Investig 2020
1
100

Case of lipoatrophic diabetes induced by juvenile dermatomyositis.
Yusuke Baba, Hiyori Kaneko, Minoru Takemoto, Kana Ide, Yuki Haga, Tatsuo Kanda, Shinsuke Akita, Yoshitaka Kubota, Masayuki Kuroda, Yutaka Kitagawa,[...]. J Diabetes Investig 2017
1
100

Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene.
Zhimin Huang, Juan Liu, Kaka Ng, Xuesi Wan, Lijuan Xu, Xiaoying He, Zhihong Liao, Yanbing Li. J Diabetes Investig 2018
2
50



Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial.
Kohzo Takebayashi, Kenji Hara, Tomoko Terasawa, Rika Naruse, Mariko Suetsugu, Takafumi Tsuchiya, Toshihiko Inukai. Endocr J 2017
17
10

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.
E W Iepsen, J Lundgren, C Dirksen, J-Eb Jensen, O Pedersen, T Hansen, S Madsbad, J J Holst, S S Torekov. Int J Obes (Lond) 2015
44
10

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
Dustin M Lee, Micah L Battson, Dillon K Jarrell, Shuofei Hou, Kayl E Ecton, Tiffany L Weir, Christopher L Gentile. Cardiovasc Diabetol 2018
71
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.